目的：探讨文拉法辛缓释片与帕罗西汀治疗无精神病性症状抑郁症的临床疗效和安全性。方法将84例无精神病性症状的抑郁症患者随机分为两组，每组42例，观察组口服文拉法辛缓释片治疗，对照组口服帕罗西汀治疗，观察8周。治疗前后采用汉密顿抑郁量表评定临床疗效，副反应量表评定不良反应。结果治疗2周末观察组汉密顿抑郁量表评分较对照组下降更显著（ P＜0．01）；治疗8周末，观察组总有效率为78．57％，对照组为76．19％，两组总有效率比较差异无显著性（P＞0．05）。两组不良反应均较轻微，发生率比较差异无显著性（P＞0．05）。结论文拉法辛缓释片与帕罗西汀治疗抑郁症效果均显著，安全性高、依从性好，但文拉法辛缓释剂起效更快，值得临床推广应用。%Objective To explore the efficacy and safety of venlafaxine sustained-release tablets vs .parox-etine in depression without psychotic symptoms .Methods Eighty-four depression patients without psy-chotic symptoms were randomly assigned to two groups of 42 ones each ,observation group took orally venlafaxine sustained-release tablets and control group did paroxetine for 8 weeks .Clinical efficacies were assessed with the Hamilton Depression Scale (HAMD) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 2nd week the HAMD score lowered more significantly in observation than control group (P<0 .01);at the end of the 8th week total effective rate were respectively 78 .57% in observation and 76 .19% in control group ,which showed no significant difference (P>0 .05) .Adverse reactions of both groups were mild ,their incidences had no significant group differences (P>0 .05) .Conclusion Both venlafaxine sustained-release tablets and parox-etine have an evident effect in depression ,higher safety and better compliance ,but the former takes effect more rapidly and deserves to be clinically spread and utilized .
展开▼
